SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD. Ratings Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Deutsche Boerse AG
Equities
08HH
CNE100001M79
|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.532 EUR | -6.36% |
|
-1.10% | -20.02% |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The group shows a rather high level of debt in proportion to its EBITDA.
- The company is highly valued given the cash flows generated by its activity.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -20.02% | 7.89B | - | ||
| +48.79% | 781B | C+ | ||
| +41.37% | 639B | B | ||
| +19.43% | 330B | B- | ||
| +7.18% | 293B | C+ | ||
| +17.26% | 248B | B+ | ||
| -0.20% | 221B | A+ | ||
| +11.55% | 217B | B- | ||
| +4.53% | 162B | C+ | ||
| -3.92% | 157B | C+ |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 600196 Stock
- 08HH Stock
- Ratings Shanghai Fosun Pharmaceutical (Group) Co., Ltd.